Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

OTO-313 well tolerated and promising for treating tinnitus

April 12, 2021

Positive 12-month data presented from phase II TOPAZ study of apitegromab in SMA

April 9, 2021

Spinal cord stimulation reduces diabetic neuropathy pain

April 9, 2021

Phase II study of MIB-626 enrolling adults with Friedreich's ataxia

April 9, 2021

Naphthalene monoimide TGR-63 for treating Alzheimer's disease

April 9, 2021

SMN gene therapy can result in too much of a good thing

April 8, 2021

Subcutaneous injection of Tysabri approved in Europe for relapsing-remitting MS

April 8, 2021

Vincere Biosciences presents new USP30 inhibitors

April 8, 2021

Recognify Life Sciences initiates phase IIa trial of RL-007 in CIAS

April 7, 2021

Oryzon announces preclinical collaboration with Seaver Autism Center at Mount Sinai

April 7, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...